Alvarez-Llamas Gloria, Santiago-Hernandez Aranzazu, Ruilope Luis M
Immunology Department, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain.
Cardiorenal Translational Laboratory, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
Clin Kidney J. 2022 Jan 12;15(7):1217-1220. doi: 10.1093/ckj/sfac007. eCollection 2022 Jul.
Subjects not meeting KDIGO criteria for chronic kidney disease (CKD), i.e. normoalbuminuric (urinary albumin:creatinine ratio, UACR <30 mg/g) individuals with an estimated glomerular filtration rate >60 mL/min/1.73 m, are considered at no increased cardiovascular or kidney risk associated with kidney disease, but the incidence of subclinical atherosclerosis, cardiovascular events and CKD progression is already increased in the high-normal UACR range (10-30 mg/g). Earlier intervention in this subclinical pre-CKD stage may diminish cardiorenal risk. However, tools to predict albuminuria development and to identify those subjects who will benefit most from intervention are limited. Recent data have identified urine molecular changes within the normoalbuminuria condition, consisting of an altered urinary peptidome, proteome and metabolome, which represent subclinical organ damage and processes such as inflammation, oxidative stress, tricarboxylic acids cycle deregulation, impaired fatty acids β-oxidation or defective tubular reabsorption.
未达到慢性肾脏病(CKD)改善全球肾脏病预后组织(KDIGO)标准的受试者,即估算肾小球滤过率>60 mL/min/1.73 m²的正常白蛋白尿(尿白蛋白:肌酐比值,UACR<30 mg/g)个体,被认为不存在与肾脏疾病相关的心血管或肾脏风险增加的情况,但在UACR处于高正常范围(10 - 30 mg/g)时,亚临床动脉粥样硬化、心血管事件和CKD进展的发生率已经升高。在这个亚临床CKD前期阶段进行早期干预可能会降低心肾风险。然而,预测白蛋白尿发展以及识别那些将从干预中获益最大的受试者的工具有限。最近的数据已经确定了正常白蛋白尿状态下尿液分子的变化,包括尿肽组、蛋白质组和代谢组的改变,这些变化代表了亚临床器官损伤以及炎症、氧化应激、三羧酸循环失调、脂肪酸β氧化受损或肾小管重吸收缺陷等过程。